The United Kingdom and the United States have established a key bilateral deal that will maintain zero import taxes on UK pharmaceutical exports entering the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to raise spending on medicines through the public health system. This commitment guarantees that import taxes on these vital goods will stay at nothing for a period of 36 months.
This deal follows earlier threats to hike tariffs on branded pharmaceutical products, with increases discussed as high as double the cost.
"This deal between the Britain reinforces the worldwide climate for cutting-edge drugs and brings much-needed balance to transatlantic pharmaceutical trade," a statement noted.
Commercial Significance
Drugs are one of the UK's most significant goods shipped to the United States, which is clearly the primary market for major UK drugmakers.
Export figures indicate that in the 12 months prior to the third quarter, the UK exported drugs worth £11.1bn to the US. This figure accounted for a significant portion of all goods exports in that period.
"This deal safeguards jobs, stimulates investment and sets the stage for the UK to emerge as a worldwide center for biotech and pharma," a minister stated.
Detailed British Pledges
The agreement includes several key pledges from the United Kingdom:
- Price Threshold Increase: The UK will lift the cost ceiling at which it deems new medicines to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a aim to raise total NHS spending on treatments from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The sum manufacturers must pay back to the NHS to control costs will be capped at 15%. Previously, rebates topped 20%.
Recent Tensions
The deal follows a protracted dispute between the drug companies and the UK government over medicine costs and regulatory access.
This friction were exacerbated by claims that US consumers were paying several times more for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar expansions have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS had to spend more on medicines, noting that its spending on drugs had declined as a percentage of its resources over the past decade.
